Skip to main content

Advertisement

SpringerLink
Log in

R&D productivity: on the comeback trail

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Number and aggregate peak sales value of new therapeutic drugs by year of FDA approval.
Figure 2: R&D productivity data.

References

  1. Tollman, P. et al. Identifying R&D outliers. Nature Rev. Drug Discov. 10, 653–654 (2011).

    Article  CAS  Google Scholar 

  2. Ringel, M. et al. Does size matter in R&D productivity? If not, what does? Nature Rev. Drug Discov. 12, 901–902 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Boston Consulting Group, Münstergasse 2, Zürich, 8001, Switzerland

    Ulrik Schulze & David Greber

  2. The Boston Consulting Group, Ludwigstraße 21, München, 80539, Germany

    Mathias Baedeker

  3. The Boston Consulting Group, The New Otani Garden Court, 4–1, Kioi-cho, Chiyoda-ku, Tokyo, 102–0094, Japan

    Yen Ting Chen

Authors
  1. Ulrik Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathias Baedeker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yen Ting Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Greber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrik Schulze.

Ethics declarations

Competing interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.

Supplementary information

Supplementary information S1 (box)

Data and analysis (PDF 70 kb)

Supplementary information S2 (figure)

Aggregate industry spending on research and development. (PDF 202 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schulze, U., Baedeker, M., Chen, Y. et al. R&D productivity: on the comeback trail. Nat Rev Drug Discov 13, 331–332 (2014). https://doi.org/10.1038/nrd4320

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4320

  • Springer Nature Limited

This article is cited by

Search

Navigation